Novo Nordisk's Ozempic Reduces Death Risk by 20% in FLOW Trial

May 24, 2024, 11:23 AM

Novo Nordisk's diabetes drug Ozempic has shown significant benefits in a recent trial involving patients with type 2 diabetes and chronic kidney disease. The study, known as the FLOW trial, revealed that Ozempic cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Additionally, the drug significantly reduced the risk of major kidney disease events and slowed the progression of diabetic kidney disease. Over a three-year period, treating 39 patients with Ozempic would prevent one death. These findings highlight Ozempic's potential to transform treatment for patients suffering from these conditions.